Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724444 | 0.80 | PDE4A (0.44) | PDE4APDE4CPDE4DKDM4ELMNA | |
| SCHEMBL30657578 | 0.80 | PDE4A (0.44) | PDE4APDE4CPDE4DKDM4ELMNA | |
| SCHEMBL29461538 | 0.78 | MGAM (0.40) | PDE4APDE4CPDE4DKDM4EMEN1 | |
| SCHEMBL244946 | 0.78 | MGAM (0.40) | PDE4APDE4CPDE4DKDM4EMEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL3176306 | 0.76 | KDM4E (0.49) | PDE4APDE4CPDE4DKDM4ELMNA | |
| SCHEMBL4293313 | 0.76 | PDE4A (0.46) | PDE4APDE4CPDE4DMETAP2METAP1 | |
| SCHEMBL538501 | 0.75 | PDE4A (0.44) | PDE4APDE4CPDE4DKDM4ELMNA | |
| SCHEMBL1545449 | 0.75 | PDE4A (0.51) | PDE4APDE4CPDE4DKDM4ELMNA | |
| SCHEMBL30344840 | 0.74 | CYP3A4 (0.52) | PDE4APDE4CPDE4DMEN1KMT2A | |
| SCHEMBL1543342 | 0.74 | CYP3A4 (0.52) | PDE4APDE4CPDE4DMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-8461083-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2013-06-11 | — | — | US | disclosed |
| EP-2265120-B1 | HERBICIDAL COUMPOUNDS | SYNGENTA LTD (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20110021352-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2265120-A1 | HERBICIDAL COUMPOUNDS | Syngenta Limited (GB) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115788-A1 | HERBICIDAL COUMPOUNDS | SYNGENTA LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021352-A1 | HERBICIDAL COMPOUNDS | RDX, NQO2, DDT | PDE4A 773/4885PDE4C 452/4885PDE4D 437/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | PDE4A 1051/4885PDE4C 1022/4885PDE4D 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.